Table 1.
Baseline patient characteristics.
| Characteristics | Discovery Cohort (n = 30) |
Validation Cohort 1 TCGA-LIHC (n = 192) |
Validation Cohort 2 LINC-JP (n = 142) |
p |
|---|---|---|---|---|
| Age (year) | 66 (56, 68) | 59.5 (51, 69) | 69 (62, 75) | <0.001 |
| Gender | 0.649 | |||
| male | 20 | 139 | 97 | |
| female | 10 | 53 | 45 | |
| AFP (ng/mL) | 73.5 ± 168.2 | 186.6 ± 496.6 | NA | 0.765 |
| T stage | 0.920 | |||
| T1 | 23 | 148 | NA | |
| T2 | 7 | 43 | NA | |
| Tumor stage | <0.001 | |||
| stage I | 23 | 149 | 36 | |
| stage II | 7 | 43 | 106 | |
| Histology grade | 0.006 | |||
| G1 | 6 | 21 | 17 | |
| G2 | 14 | 93 | 83 | |
| G3 | 10 | 65 | 31 | |
| G4 | 0 | 11 | 0 | |
| Treatment methods | <0.001 | |||
| segmentectomy | 19 | 103 | 2 | |
| lobectomy | 8 | 70 | 0 | |
| extended lobectomy | 3 | 7 | 0 | |
| total hepatectomy with transplant | 0 | 1 | 0 | |
| TACE | 0 | 0 | 25 | |
| chemotherapy | 0 | 0 | 1 | |
| Follow-up duration (day) | 552.0 (383.5, 1459.0) | 631.5 (381.2, 1289.0) | 870.0 (570.5, 1132.5) | 0.899 |